Chugai Pharma & Rani Therapeutics ink agreement to develop and commercialize oral formulation leveraging RaniPill technology: Tokyo Wednesday, October 22, 2025, 12:00 Hrs [IST] Ch ...

Pfizer’s phase 2 PHAROS trial of Braftovi plus Mektovi shows sustained long-term survival in patients with advanced lung cancer: New York Wednesday, October 22, 2025, 11:00 Hrs ...

Roche’s Gazyva/Gazyvaro receives US FDA approval for the treatment of lupus nephritis: Basel Wednesday, October 22, 2025, 10:00 Hrs [IST] Roche announced that the US Food and Dr ...

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose: Paris Wednesday, October 22, 2025, 09:00 Hrs [IS ...

Govt should mandate PG cos to supply small quantities 'as required' by MSMEs to halt contamination: TN IDMA: Peethaambaran Kunnathoor, Chennai Wednesday, October 22, 2025, 08:00 H ...

Health ministry to mandate tracking mechanism for vaccines, antimicrobials, cancer and N&P drugs: Gireesh Babu, New Delhi Wednesday, October 22, 2025, 08:00 Hrs [IST] The Union mi ...

Govt discusses challenges faced by exporters during import, export clearance of temperature sensitive consignments: Shardul Nautiyal, Mumbai Wednesday, October 22, 2025, 08:00 Hrs ...

The Union health ministry has proposed an amendment to the Schedule K of the Drugs Rules, 1945, to move all oral formulations with higher alcoholic content more than 30 ml to Schedule H1 for enhanced ...

Centre to amend Drugs Rules related to licensing of stem cell derived & gene therapy products: Gireesh Babu, New Delhi Wednesday, October 22, 2025, 08:00 Hrs [IST] The Union minis ...

Thermo Fisher expands global footprint in North America & Europe for sterile drug product development and commercial manufacturing: Waltham, Massachusetts Friday, December 11, 202 ...

Renalys Pharma reaches Japan PMDA agreement on phase III trials of sparsentan for FSGS and Alport syndrome: Tokyo, Japan Monday, October 20, 2025, 18:00 Hrs [IST] Renalys Pharma, ...

US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty: Incheon, South Korea Monday, October 20, 2025, 17:00 Hrs [IST] Celltrion, ...